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Abstract
CD23 is atypically highly expressed in various chronic diseases, including B-CLL, lupus erythematodes and rheumatoid arthritis. Its
expression can be further enhanced by interleukin 4 (IL-4). We have shown before that in B-CLL cells nuclear factor(s) of activated T cells
(NF-ATs) show permanent nuclear localization and therefore constitutive transcriptional activity. Here we identify CD23b promoter as a
novel target for NF-AT factors in B-CLL cells. The CD23b promoter contains two NF-AT binding sites to which NF-ATp and NF-ATc factors
bind with high affinity. Mutations introduced into these sites abolished NF-AT binding and impaired the promoter activity, as did cyclosporin
A (CsA), an inhibitor of nuclear transport of NF-ATs. Furthermore, we show that IL-4-induced transcription factor STAT6 cooperates with
NF-ATs in the induction of the CD23b promoter activity. These results show that the CD23b promoter is a target for NF-AT factors and
suggest that the cooperation between NF-AT and STAT factors might be one of the molecular mechanisms responsible for high-level
expression of CD23 on the surface of B-CLL cells.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
CD23 (also designated as FcqRII) is the low affinity
receptor for IgE, which is expressed on numerous haema-
topoietic cells including B cells, T cells and monocytes [1].
In these cells CD23 mediates a variety of biological activ-
ities [2,3]. High CD23 expression is a typical property of
various chronic diseases, such as B-CLL, rheumatoid arthri-
tis and lupus erythematodes. It is assumed that signalling
through CD23 contributes to the pathogenesis of these
diseases [4,5].
CD23 is involved in regulation of IgE synthesis, IgE-
dependent presentation of antigens to T cells and prolifer-
ation of myeloid precursors. Two isoforms, CD23a and
CD23b, are described which differ only in a short amino
acid sequence at the N-terminus. It was suggested that these
differences are sufficient to propagate different signals after
receptor ligation. CD23a is exclusively expressed on B
cells, whereas CD23b is also expressed on a variety of cells
of the myeloid lineage after stimulation. CD23a exhibits an
endocytosis signal that renders it efficient in antigen uptake
[6]. Ligation of CD23 was shown to trigger nitric oxide
production and to induce the production of TNFa , cAMP
and interleukin-10 (IL-10) [7,8]. The anti-apoptotic activity
of nitric oxide has been discussed as a mechanism contri-
buting to the prolonged viability of B-CLL cells [9].
The expression of the two isoforms is regulated by the
use of two different promoters and alternative splicing
events. The CD23b promoter is located between exon II
and exon Ib (Fig 1A). So far, binding sites for STAT6,
STAT1 and AP-1 family factors have been described to be
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responsible for the transcriptional activity of the CD23b
promoter [10,11].
IL-4 is the most potent inducer of CD23 expression [12].
IL-4 is mediating the translocation of the transcription factor
STAT6 to the nucleus where STAT6 binds to the promoters
of IL-4 responsive genes [13]. In addition to IL-4, mitogens
such as phorbol-myristate acetate (PMA) also exert a strong
stimulatory effect on CD23 expression in B-CLL, but only a
weak one in normal B cells [14,15,16]. IFNg reduces IL-4-
mediated CD23 expression in normal B cells but augments
CD23 expression in B-CLL cells, further emphasizing
atypical regulation of CD23 expression in B-CLL. This also
suggests that the IL-4-mediated activation of STAT6 is not
the only signalling pathway activating the CD23 promoters
in these cells. Moreover, B lymphocytes from STAT6-
deficient mice were still found to express CD23 after
stimulation with CD40 and IL-4 [17]. The analysis of
numerous transcription factors, which are highly expressed
in lymphoid cells, resulted in the detection of constitutive
activity of several factors in B-CLL cells. Among them was
NF-ATp, a member of the nuclear factor(s) of activated T
cells (NF-AT) transcription factor family [18].
NF-AT proteins are characterized by a highly conserved
DNA binding domain of approximately 300 amino acid
residues and the control of their nuclear transport by
calcineurin, a Ca + /calmodulin-dependent protein phospha-
tase [19,20]. Among the four genuine NF-AT factors, NF-
ATp and NF-ATc (also designated as NF-AT1 and 2, or NF-
Fig. 1. NF-ATp and STAT6 collaborate in the induction of the CD23b promoter. (A) Schematic structure of the CD23 gene and localization of the CD23a and b
promoters (adapted according to Ref. [1]). (B) Sequence of the CD23b promoter. The sequence motifs for the binding of NF-AT and STAT factors are indicated.
The transcriptional start sites are marked by arrows. The translational start codon is indicated by +1; exon II sequences are underlined. (Note that the nucleotide
positions are labelled according to Ref. [1] and refer to the translational start site). (C) NF-ATp and STAT6 enhance CD23 induction. Expression vectors
encoding both factors were co-transfected as indicated into Jurkat T cells together with luciferase reporter gene constructs under the control of a wild-type
(CD23b-luci) or a mutated (CD23bM-luci, GG to CC mutations within the NF-AT-I site, positions 152/151) CD23b promoter. Five hours later, the cells
were left uninduced (W/O) or induced by TPA+ Ionomycin (T/I) for 20 h (left part of the panel). The experiment with the wild-type CD23b-promoter (CD23b-
luci) was also performed in Jurkat T cells, El-4 and 293 cells in the absence (T/I) or presence of CsA (100 ng/ml; T/I + CsA) (right part of the panel).
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ATc2 and c1, respectively) are highly expressed in periph-
eral lymphoid cells and known to bind to and control the
promoters and enhancers of numerous genes. Most prom-
inent targets for NF-AT factors in T cells are those of
lymphokine genes IL-2, IL-3, IL-4, IL-5, TNFa and GM-
CSF. Further targets are the promoters of FasL- and CD40L.
Consensus sites for NF-AT (+AP-1) factors were detected
in a large number of promoters/enhancers controlling the
expression of genes, which regulate the cell cycle, Ca+
metabolism and apoptosis of T cells [21]. Although NF-
ATp and NF-ATc are also highly expressed and induced by
Ca+ signals in B cells, there are only a few published data
concerning the role of NF-AT factors on particular gene
expression in B cells and B cell-derived leukemias/lympho-
mas [18,22,23].
The constitutive nuclear localization (and supposedly
transcriptional activity) of NF-ATp in B-CLL cells [18]
prompted us to investigate whether the CD23 promoters
are regulated by NF-AT factors in these cells. Inspection of
the promoter DNA sequences revealed three putative NF-AT
binding sites, one within the CD23a promoter and two
within the CD23b promoter. Whereas DNA/protein binding
studies specify the CD23a promoter site as a very weak one,
those from the CD23b promoter are bound by NF-AT
factors with high affinity. Moreover, we show that in
transient transfection experiments using NF-ATp and
STAT6 expression vectors, the induction of the CD23b
promoter is strongly enhanced after TPA and ionomycin
treatment of the cells. While NF-ATp or STAT6 expression
alone resulted in a moderate 2–5-fold increase of CD23b
promoter activity, co-expression of both factors led to a 15–
30-fold increase. This increase was impaired by cyclosporin
A (CsA), an inhibitor of nuclear translocation of NF-ATs,
and by the site-specific mutation introduced into these two
NF-AT sites. These results indicate that CD23b promoter (i)
is a target for NF-AT factors; (ii) its induction is controlled
by the concerted action of NF-ATp and STAT6 which both
bind directly to this promoter with high affinity; and (iii)
constitutive nuclear localization of NF-AT factors in B-CLL
cells contributes to the malignant phenotype of B-CLL cells,
which is characterized by atypically high level of CD23
expression.
2. Materials and methods
2.1. Preparation of B-CLL cells, cultivation and transfection
of cell lines
B-CLL cells were isolated from peripheral blood of 10
different untreated patients who gave informed consent. Cell
surface phenotyping revealed a staining pattern typical for B-
CLL cells (i.e. CD5+, CD19+, CD23+, CD40+, HLA class II +,
CD10 and low level expression of light chain restricted
surface IgM). B-CLL cells were purified by the centrifugation
through a Ficoll–Hypaque gradient at 900 g. T cells
were removed by E-rosetting using AET-treated sheep eryth-
rocytes. The final purity of B-CLL cells was estimated 99%.
When necessary, B-CLL cells as well as human Jurkat T
leukemia cell line were cultured in RPMI 1640 medium
supplemented with 5 mM L-glutamin, 100 U/ml penicillin
G, 100 Ag/ml streptomycin and 5% fetal calf serum (FCS)
(Gibco). HEK293 cell line was cultured in DMEM medium
supplemented with 10% FCS. Both Jurkat and HEK293 cells
were transfected using SuperFect reagent (Qiagen, Germany)
according to the manufacturer’s protocol. Five hours after
transfection, the cells were treated with TPA (20 ng/ml) and
ionomycin (0.5 mM) in the presence or absence of CsA (100
ng/ml). After 20 h of incubation cellular extracts were
prepared and luciferase activities determined using a lumin-
ometer (Berthold).
2.2. Plasmids
The CD23b promoter–luciferase reporter construct (Fig.
1A and B) was created on the basis of plasmid pLuc + vector
[24]. Point mutations abrogating the binding of NF-AT
factors were introduced using QuikChange mutagenesis
system (Stratagene) and following oligonucleotides NF-
AT-IM ( 160 to  135): 5V-GAAGGAGTCCAAAATT-
GAGGGCCCCT-3V, and NF-AT-IIM ( 251 to  226): 5V-
TCCCTCTCTGCCAAAGAGG GTGAATT-3V). Mutated
positions within the underlined ‘core’ sequence are shown
in bold letters. The sequence of all luciferase reporter
constructs was confirmed by DNA sequencing. Expression
vectors for NF-ATp, NF-ATc/A, STAT5 and a constitutive
version of STAT5 (STAT5-CA) have been published pre-
viously [25,26]. The STAT6 expression vector was kindly
provided by Dr. E. Pfitzner and contains a full size human
STAT6 cDNA cloned in vector pXM.
2.3. Nuclear extracts and electrophoretic mobility shift
assays (EMSAs)
Nuclear protein extracts from B-CLL cells were prepared
as described [27] with slight modifications. NP40 was
omitted and nuclei were released by passing the cells five
times through an injection needle (26g3/8). In EMSAs, 5 Ag
of nuclear proteins was incubated with 40,000 cpm (equiv-
alent to approximately 0.3 ng) of g32P-labelled double-
stranded oligonucleotides as probes in the presence of 1
Ag poly(dI–dC) as unspecific competitor and increasing
amount (12.5–50 ng) of specific competitors, when indi-
cated. After incubation on ice for 30 min, the samples were
fractionated on nondenaturing 5% polyacrylamide gels at 15
V/cm at room temperature followed by autoradiography. In
EMSA ‘‘super-shift’’ assays, 1 Ag of polyclonal antibodies
raised against STAT5 (Santa Cruz, sc-1656X), STAT6 (sc-
981X), NF-ATp (sc-7295X) or NF-ATc (ABR) was added to
binding reactions. The following double-stranded oligonu-
cleotides were used as probes: the distal NF-AT site from the
murine IL-2 promoter: (Pu-bd-IL-2 5V-tcgaCAAAGAG-
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GAAAATTT GTTTCATACAGAAG-3V); the NF-AT sites
from the CD23b promoter: (NF-AT-I ( 160 to  135): 5V-
tcgaGAAGGAGTGGAAAATTGAGGGCCCCT-3V, NF-
AT-II ( 251 to  226): 5V-tcgaTCCCTCTCTGGGAAA-
GAGGGTGAATT-3V); and NF-AT-like site from the
CD23a-promoter ( 28 to  9): 5V-tcgaTTAGGTCTAT-
GAAAATAGAAGCTGTC-3V. Small letters indicate linker
nucleotides; conserved ‘core’ nucleotides are shown in bold
letters.
2.4. DNase I footprint protection assays
For DNase I footprinting assays, end-labeled DNA
probes were prepared using [g-32P]ATP and T4 polynukleo-
tide kinase; 104 cpm (ca. 0.2 ng) of labelled DNA fragments
was used per binding reaction. Recombinant proteins from
transformed E. coli BL21-DE bacteria were purified over
Glutathione–Sepharose column (Amersham-Pharmacia)
according to the specifications of manufacturer. In DNase
I footprinting reactions, labeled DNA fragments were incu-
bated for 1 h with increasing amounts (0.25–1.5 Ag) of
glutathione-S-transferase (GST) or GST–NF-ATp fusion
protein [28] representing the DNA-binding domain of
murine NF-ATp. After limited DNase I digestion, the
samples were purified by organic extraction, DNA was
precipitated and fractionated on 6% polyacrylamide/7 M
urea DNA sequencing gels followed by autoradiography.
3. Results
The constitutive nuclear residence of NF-ATp in B-CLL
cells [18] suggested that NF-AT transcription factors might
exert an important role in the control of genes which are
highly expressed in B-CLLs, such as CD23. To test this
hypothesis, we co-transfected luciferase reporter genes con-
trolled by the CD23a or CD23b promoter (Fig. 1C) with
expression vectors encoding either NF-ATp or NF-ATc/A
(the most abundant NF-ATc isoform in T effector cells
[25,29]) into human Jurkat T cells or HEK 293 cells. In
both cell types, expression of NF-ATp had a weak but
reproducible stimulatory effect on the CD23b promoter-
controlled increase of luciferase activity after treatment of
cells with TPA and ionomycin (T + I) (Fig. 1C, left panel).
No effect was observed on the CD23a promoter after
transfection with the NF-ATc/A expression vector (results
not shown). Since IL-4 is the most potent known inducer of
CD23 expression and the IL-4-induced factor STAT6 binds
to the CD23b promoter [16,11], we tested next whether
STAT6 (or STAT5, also induced by IL-4: [30]) is able to
collaborate with NF-ATp to enhance the induction of
CD23b promoter. Indeed, a strong stimulatory effect on
the T + I induction of the CD23b promoter was observed
when NF-ATp was transfected along with vectors encoding
either STAT6 (Fig. 1C, left panel) or STAT5 (data not
shown). While transfection of vectors expressing either
NF-ATp or STAT6 resulted in a 2–5-fold induction, co-
transfection of NF-ATp expression vector together with one
of the two STAT vectors resulted in a 20–50-fold increase
of CD23b promoter activity in Jurkat (Fig. 1C) or HEK293
cells (data not shown). A strong repression of this induction
was observed when Jurkat cells were induced by T + I in the
presence of 100 ng/ml CsA, an inhibitor of calcineurin and
therefore suppressor of nuclear translocation of NF-ATs. A
similar CsA-mediated repression of NF-ATp + STAT6-medi-
ated increase of CD23 activity was observed in HEK293
cells and murine EL-4 thymoma cells (Fig. 1C). This
indicates that NF-ATp and STAT6 (or STAT5) can cooperate
in the induction of the CD23b promoter.
Sequence inspection of the CD23b promoter revealed
several putative NF-AT binding sites. As the first step in
order to determine whether these sites might interact with NF-
AT proteins, we tested the binding of bacterially expressed
GST–NF-ATp fusion protein to the CD23b promoter in
DNase I footprint protection assays, which identified several
‘‘would-be’’ regions of interaction (see Fig. 2). The most
prominent one harboring the TGGAAAA core sequence
spans the nucleotides from position  160 to  141 and
was designated as NF-AT-I. A second motif (designated
Fig. 2. NF-ATp binds to the CD23b promoter. DNase I footprint protection
assay. A 32P-labelled CD23b promoter probe was incubated with increasing
amounts (0.25–1.5 Ag) of GST protein (lanes 2 + 3 and 8 + 9) or GST–
NFATp fusion protein (lanes 4–6 and 10–12). Samples were digested by
DNase I and fractionated on a 6% polyacrylamide sequencing gel. G-
specific DNA sequencing reactions of the CD23b promoter are shown in
lanes 1 and 7. The sequences of the NF-ATp-specific footprints over the
NF-AT-I and NF-AT-II sites are indicated; the NFAT core sequences are
shown in boldface letters.
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as NF-AT-II) bearing a slightly modified version of this
sequence is located just 10 nucleotides 3Vfrom the known
STAT 6 binding site. This is reminiscent to the configuration
of composite NF-AT+AP-1 binding sites, which occur
approximately 10 times more frequent in promoters of genes
which are expressed upon T cell activation than in promoters
active in other tissues [21]. Those have the general structure
5V-caxwGGAAAawxxxg/a TGAC/GTCAg/tc-3’ (where
capital letters denote highly, lower case letters poorly, con-
served nucleotides; w=A or T; x=any nucleotide), i.e. the AP-
1 site is located about 10 nucleotides 3V from the NF-AT
‘core’ motif as the STAT 6 site in the context of CD23b
promoter NF-AT-II site (see Fig. 1B).
DNase I protection assays are performed at relatively
high concentration of recombinant fusion protein, which
may manifest significantly relaxed binding requirements in
comparison to the native transcription factors. Therefore, we
tested putative NF-AT binding sites in EMSA assays using
nuclear extracts prepared from B-CLL cells (Fig. 3A).
Oligonucleotides containing NF-AT-I or NF-AT-II sites
(see Section 2) were included as competitors in EMSA
using the high affinity distal NF-AT binding site (Pu-bd-IL-
2) from the murine IL-2 promoter [31] as a probe. A 10-fold
molar excess of NF-AT-I or NF-AT II site was sufficient to
suppress NF-AT complexes generated with nuclear proteins
from B-CLL cells and the distal IL-2 NF-AT site (Fig. 3A,
lanes 6–8 and 9–11, respectively). A similar effect was
detected with a 10-fold molar excess of the unlabelled distal
IL-2 site but not with a 10- or 100-fold excess of the NF-AT-
like putative binding site from the CD23a promoter (Fig.
3A, lanes 3–5). This indicates that NF-AT-I and NF-AT-II
sites from the CD23b promoter correspond to rather high
affinity NF-AT binding sites.
In order to show which NF-AT proteins bind to the
CD23b promoter in B-CLL cells, we performed EMSA
supershift assays using the NF-AT sites I and II and nuclear
proteins from nontreated and T+I-treated B-CLL cells. As
shown in Fig. 3B (lanes 5–9), incubation of EMSAs with
antibodies raised against NF-ATp or NF-ATc led to the
generation of specific ‘supershift’ complexes. This indicates
that in nuclear protein extracts from B-CLL cells, NF-ATp
and NF-ATc are prominent proteins binding to the CD23b
promoter. Next, we investigated whether the binding of NF-
AT factors to the NF-AT-I and/or NF-AT-II sites contributes
to the induction of CD23b promoter activity by NF-ATp and
STAT6. Introduction of GG to CC mutations into the core
Fig. 3. NF-ATp and NF-ATc bind to the NF-AT-I site of the CD23b promoter in nuclear protein extracts from B-CLL cells. (A) EMSA competition assays. Five
micrograms of nuclear proteins isolated from uninduced B-CLL cells was incubated with the high affinity distal NF-AT binding site (Pu-bdIL-2) from the murine
IL-2 promoter. For specific competition, a 10-fold molar excess of the cold probe (lane 2), a 10-, 100- or 1000-fold excess of the NF-AT-like site from the
CD23a promoter (Site A) or of the NF-AT-I and NF-AT-II sites from the CD23b promoter were added. NS, nonspecific complex. (B) EMSA supershift assays.
In lanes 1–4, nuclear proteins from uninduced (lane 1) or IL-4-induced B-CLLs (lanes 2–4) were incubated with a probe of the STAT6 site; in lanes 5–9,
nuclear proteins from uinduced (lane 5) or T + I-induced B-CLLs (lanes 6–9) were incubated with a probe of NF-AT-I site from the CD23b promoter. In
supershift assays, antibodies raised against STAT5 (lane 3), STAT6 (lane 4), NF-ATp (lane 7), NF-ATc (lane 8) or both NF-ATs (lane 9) were added. The
STAT6-specific and the STAT6-supershift complex (S6-SS) are indicated by arrowheads. NF-AT complexes are indicated by a bracket. The filled square
indicates the NF-ATp supershift complex; asterisks indicate NF-ATc-specific supershift complexes.
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motifs of NF-AT-I (positions 152/ 151) or NF-AT-II
sites (positions 241/ 240) completely abolished any
NF-AT binding and competition with the NF-AT binding
to Pu-bd-IL-2 probe in EMSAs (data not shown). While the
NF-AT-II mutation had only marginal effect on the activity
of CD23b promoter (around 2-fold reduction, data not
shown), the mutation of NF-AT-I site (positions 152/
 151, Fig. 1B) exerted deleterious effect on the induction
of CD23b promoter activity (Fig. 1C, middle panel). In
particular, the strong increase in constitutive and inducible
activity of the CD23b promoter mediated through the
collaboration between NF-ATp and STAT6 factors was
abolished when a promoter bearing a defective NF-AT-I
site was used in the transfection assays (Fig. 1C).
We also tested whether STAT5 or STAT6 is the most
prominent STAT factor binding to the CD23b promoter in
B-CLL cells following IL-4 induction. As shown in Fig. 3B
(lanes 1–4), incubation with a STAT6, but not with a
STAT5-specific antibody, led to the complete supershift of
the STAT complex. This indicates that in agreement with our
former published data, STAT6 is the most prominent STAT
factor binding to the CD23b promoter after IL-4 treatment
of B-CLL cells.
4. Discussion
There are several T/A GGAA sequence motifs within the
CD23b promoter to which NF-AT factors appear to bind
(Fig. 2). We have shown here that NF-AT factors bind to
two sites of the promoter, i.e. to NF-AT-I and NF-AT-II, with
high affinity (Fig. 3). Similar to the strong binding of NF-
AT to composite NF-AT/AP-1 motifs [19], the binding of
NF-ATs to the composite NF-AT/STAT binding site could
facilitate NF-AT binding due to a collaboration between
both factors. While no direct protein–protein interactions
between NF-AT and AP-1 have been detected in solution,
AP-1 facilitates the binding of NF-AT to DNA, and numer-
ous contacts between both factors have been observed when
they are bound to a composed NF-AT/AP-1 sequence motif
[32]. In myocytes and cardiomyocytes, NF-AT factors were
found to bind to and collaborate with MEF2 or GATA-2,
respectively [33,34]. It is likely that in other cells, such as in
B-lymphocytes where NF-AT factors are expressed, partners
other than or in addition to AP-1, GATA-2 and MEF2
collaborate with NF-AT factors in gene activation.
We show here that STAT6 cooperates with NF-ATp in
the activation of the CD23b promoter. Although binding to
the composite NF-AT-II/STAT motif ( 242/ 218) was an
attractive explanation for the cooperation between the NF-
AT and STAT factors, mutations introduced into the NF-AT-
II (positions 241/ 240) site had only marginal effect on
the activity of a reporter construct. Deleterious effect from
the mutations at positions  152/ 151 indicates that in the
case of CD23b promoter, the cooperation between the NF-
AT and STAT factors is mainly going through the separate
NF-AT-I ( 153/ 148) and STAT ( 226/ 218) binding
sites (Fig. 1A,B).
Another promoter that harbors multiple NF-AT and
STAT5/6 binding sites is the inducible NF-ATc promoter,
which was found to be strongly enhanced by NF-AT and
STAT6 in co-transfection experiments (Chuvpilo et al., in
preparation). It remains to be shown how NF-ATp and
STAT6, whose activities are controlled by different signal-
ling pathways, collaborate in the control of these (and
probably further) promoters, and whether this collaboration
is going through the individual or/and composite NF-AT/
STAT binding elements.
Our data indicate that the CD23b promoter is a target for
NF-ATp and NF-ATc in B-CLL cells. We expect that this is
important to understand the molecular basis of B-CLL since
CD23 has been described to play a significant role in the
control of B-CLL cell viability. It has been suggested that
the CD23a and b promoters are differently regulated in B-
CLL cells. Fournier et al. [15] reported the possibility of a
selective up-regulation of CD23b isoform by IL-2 and
IFNa, stimuli which are able to induce B-CLL growth.
Furthermore, it was suggested that selective increase in the
expression of the CD23b-isoform might provoke the entry
of resting (Go) B-CLL cells into the cell cycle [35]. While
our recent data confirm differences in the regulation of
CD23 expression between the B-CLL and normal B-cells
[36], we do not find any evidence indicating differential
regulation of two isoforms. The ratio between CD23a and
CD23b stayed between 2:1 and 3:1, regardless of the stimuli
used. Therefore, we expect that expression of CD23a and
CD23b isoforms is regulated by different, but coordinated
pathways.
In regard to the progression of B-CLL, stimulation of
membrane-bound CD23 on B-CLL cells up-regulates func-
tional iNOS enzyme, which is able to counteract the normal
apoptotic process and, therefore, may contribute to the
malignant phenotype [9,37]. We conclude that the constit-
utive nuclear expression of NFAT in B-CLL cells leads, in
concert with STAT factors, to an enhanced activation of the
CD23b-promoter, increased expression of CD23b isoform
and therefore, to enhanced viability of these malignant
cells.
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